Every Form 4 that vTv Therapeutics Inc. (VTVT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow VTVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTVT filings page.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
vTv Therapeutics Inc. reported that director Dr. Raymond Cheong received a grant of 6,000 non-qualified stock options exercisable into Class A common stock at $35.08 per share. The options vest on the earlier of June 26, 2027 or the 2027 annual shareholder meeting and expire on June 26, 2036.
According to the disclosure, the options were granted to Dr. Cheong in his capacity as a director, but the grant is reported for Baker Bros.–affiliated funds because they hold an indirect proportionate pecuniary interest. The adviser to the funds holds voting and dispositive power over the options and any resulting shares, while Dr. Cheong does not retain compensation rights under adviser policies.
SPIEGELMAN DANIEL K reported acquisition or exercise transactions in this Form 4 filing.
vTv Therapeutics Inc. director Daniel K. Spiegelman received a grant of stock options, giving him the right to buy 6,000 shares of Class A Common Stock at $35.08 per share. These options expire on June 26, 2036 and are part of his director compensation.
The options vest on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of shareholders, conditioned on his continued board service through vesting. Following this grant, Spiegelman holds options on a total of 16,000 shares.
vTv Therapeutics Inc. director Srinivas Akkaraju received a grant of stock options covering 6,000 shares of Class A common stock. The options have an exercise price of $35.08 per share and expire on June 26, 2036. According to the terms, the award vests on the earlier of June 26, 2027 and the date of the 2027 annual general meeting of shareholders, provided he continues serving on the board. Following this grant, his total directly held option awards reported in this filing increased to 16,983 derivative securities.
vTv Therapeutics Inc. director Fahed Al-Marzooqi received a grant of stock options covering 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These options vest on the earlier of June 26, 2027 and the 2027 annual general meeting of shareholders, conditioned on continued board service, and expire on June 26, 2036. Following this grant, his reported derivative holdings tied to this award total 19,555 options.
vTv Therapeutics Inc. director Anne M. Phillips received a grant of options to buy 6,000 shares of Class A common stock at an exercise price of $35.08 per share. These director stock options expire on June 26, 2036 and are part of her board compensation.
The option vests on the earlier of June 26, 2027 or the date of the 2027 annual general meeting of shareholders, provided she continues serving on the board through that date. Following this grant, she holds options covering 16,860 shares directly.
vTv Therapeutics Inc. executive vice president and CFO Michael Stephen Tung received a grant of employee stock options reported as a Form 4 transaction. The award covers 44,969 options with an exercise price of $36.92 per share, increasing his directly held option position to 89,969 options following the grant. According to the footnote, the options vest 25% on the first anniversary of the grant date and then in equal quarterly installments afterward, spreading the ability to exercise over time.
vTv Therapeutics Inc. reported an insider equity award for its President, CEO and Executive Chairperson, Paul J. Sekhri. On February 17, 2026, he was granted stock options tied to 140,000 shares of Class A common stock at an exercise price of $36.92 per share. The options vest 25% on the first anniversary of the grant date and then in equal quarterly installments. Following this grant, Sekhri’s directly held Class A interest reported in this filing totals 392,212 shares.